This article will discuss 3 possible ways of getting into the field of data science.

Bye Aerospace electric airplane, AeroShark aircraft skin, Collier Trophy finalists, hydrogen fuel-powered engine, lasers pointed at aircraft, F-35C crash video leakers, closing the airspace.

The post 693 Bye Aerospace Electric Airplane appeared first on Airplane Geeks Podcast.

Lausanne, Switzerland, and Barcelona, Spain, Mar 2, 2022 - (JCN Newswire) - Oculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics, a private translational neuroscience R&D company, today announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina.

ACT-01, which is being renamed OCS-05, is a first-in-class small molecule with neuroprotective activity that has shown positive results in animal models of neuroinflammation and neurodegeneration. Its mechanism of action is related to the activation of the trophic factor pathways such as IGF-1 and BDNF. In ophthalmology, this action can protect the nerve axons in conditions where the optic nerve is affected, such as in acute optic neuritis and glaucoma, where the OCS-05 could prevent chronic vision loss.

Based on positive preclinical data and results of a phase 1 safety and PK study in healthy volunteers, a phase 2a study was initiated (the ACUITY study).

ACUITY is a two-arm, randomized, double-blind, placebo-controlled, monocentric study to evaluate the safety and tolerability of OCS-05 compared to placebo in patients with acute optic neuritis. In addition to safety, secondary outcome measures will include optic nerve anatomical measures, as well as visual function measures. The study is ongoing at the La Pitie-Salpetriere hospital in Paris within the neurology-ophthalmology network of the Public University Hospital Group in Paris (APHP). One third of the planned sample size has been enrolled.
Oculis is currently planning the expansion of the program in ophthalmology working with the regulatory agencies in the US, EU and China amongst others.

Riad Sherif, M.D., CEO of Oculis, said: "We are excited about this agreement as it combines Oculis's ophthalmology expertise with Accure's unique neuroprotective approach to help transform the treatment of neurodegenerative diseases in ophthalmology. At Oculis, our focus is on building a highly innovative and differentiated pipeline providing life changing treatments for ocular unmet medical needs, and OCS-05 is a perfect fit for that ambition. Glaucoma is a leading global cause of irreversible blindness, and despite IOP lowering treatments, a significant proportion of patients still go blind. With OCS-05, we have the potential to bring to market the first neuroprotective for glaucoma and other optic neuropathies."

Laurent Nguyen, M.D., Co-founder and Chief Executive Officer at Accure Therapeutics, said: "Having shown promising early data and potential in a number of ocular disease indications, the timing is right for a partnership between two like-minded companies committed to patients and driven by a passion for neuroscience. By leveraging its expertise in ophthalmology, Oculis has the potential to fulfill the promise of this exciting asset in a wide range of neurodegenerative diseases."

In reference experimental animal models of acute optic neuritis (acute inflammatory demyelinating disorder of the optic nerve) and high-pressure glaucoma (high eye pressure damaging the optic nerve and leading to permanent vision loss), OCS-05 reduces damage to the optic nerve and retina. It also decreases paralysis progression in an autoimmune encephalomyelitis animal model for multiple sclerosis (inflammation caused by the body's immune system, which destroys nerve cell processes and myelin in the brain and spinal cord).

Data from a completed phase 1 study show the safety and tolerability of single and multiple doses of OCS-05 in healthy volunteers.

Under the terms of the agreement, Accure Therapeutics will receive an upfront payment, potential milestone payments upon the achievement of certain development and commercial milestones, and tiered royalties on sales.

Anthony Rosenberg, Chairman of Oculis's Board of Directors, said: "The addition of OCS-05 to Oculis's pipeline is very much in line with the Company's strategy to develop transformative therapies that address the root cause of ocular disease to improve patients' sight and quality of life. There is a clear need for first-in-class therapies that can protect and prevent damage to the optic nerve and retina. Oculis has the team and expertise to bring OCS-05 through clinical trials and ultimately to patients around the world."

Montserrat Vendrell, Chairman of Accure Therapeutics and Partner at Alta Life Sciences added: "This licensing deal with Oculis is a proof-of-concept of the value creation that Accure Therapeutics brings as a translational R&D engine, taking forward truly unique science that spun-off from the University of Barcelona. This licensing agreement will enhance Accure's capabilities to accelerate and expand value potential for the rest of its pipeline."

About Oculis
Oculis is a global biopharmaceutical company purposefully driven to save sight, improve eye care and address significant unmet medical needs with breakthrough innovations. Oculis's highly differentiated pipeline includes candidates for topical retinal treatments, topical biologics and disease modifying treatments. With a presence in key international markets, Oculis is poised to deliver life-changing treatments to patients worldwide.

Headquartered in Lausanne, Switzerland and with operations in Europe, the U.S. and China, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

About Accure Therapeutics
Accure Therapeutics is a private translational neuroscience R&D company. Based in Barcelona (Spain), it was launched in 2020 with a Series A funding led by Alta Life Sciences Spain I and supported by the Centre for Technological and Industrial Development (CDTI). This European company with an international mindset boasts a unique portfolio of three new chemical entity programs pursuing innovative targets - with potential to accommodate others. Accure aims to develop new disease modifying drugs to treat serious conditions such as optic neuritis, multiple sclerosis, Parkinson's disease and epilepsy. With an experienced business and scientific team, Accure Therapeutics is one of the few companies that operate in an agnostic fashion on initial science to deliver cutting-edge drugs in CNS.

To learn more visit https://accure.health/



Copyright 2022 JCN Newswire. All rights reserved. www.jcnnewswire.comOculis S.A., (Oculis) a global ophthalmology company developing life-changing treatments to save sight and improve eye care with breakthrough innovations, and Accure Therapeutics, a private translational neuroscience R&D company

Has an old car taken up important space in your garage or on your property? Do you want to get rid of it? However...

Quaise Energy, an MIT spinoff, has developed a unique drill technology that aims to unleash ultra-deep geothermal energy for clean, almost endless energy.  The aim is to use steam from the Earth instead of coal to repower traditional coal plants worldwide. Despite the project’s high cost, the company expects it to replace its first coal-fired […]

What happens if a judge decides the sale of Angel Stadium broke the law? Here's the breakdown of what could happen next.

***Important***Blogger is not wrote any recommendation & suggestion. All is personal opinion and reader should take their own risk in investment decision

Quantum 6, 662 (2022).

https://doi.org/10.22331/q-2022-03-01-662

For a classical channel, neither the Shannon ca-pa-city, nor the sum of conditional probabilities corresponding to the cases of successful transmission can be increased by the use of shared entanglement, or, more generally, a non-signaling resource. Yet, perhaps somewhat counterintuitively, entanglement assistance can help and actually elevate the chances of success even in a one-way communicational task that is to be completed by a single-shot use of a noiseless classical channel. To quantify the help that a non-signaling resource provides to a noiseless classical channel, one might ask how many extra letters should be added to the alphabet of the channel in order to perform equally well $without$ the specified non-signaling resource. As was observed by Cubitt, Leung, Matthews, and Winter, there is no upper bound on the number of extra letters required for substituting the assistance of a general non-signaling resource to a noiseless one-bit classical channel. In contrast, here we prove that if this resource is a bipartite quantum system in a maximally entangled state, then an extra classical bit always suffices as a replacement.

You can find the authors' online classes related to this publication here.

The topic of managing work/life balance came up during a recent meeting. Most of the group acknowledged that it’s a tricky thing to manage. It sounds like it’s just two things: work and life. But it’s so much more than that. Life is broken out into many areas such as family, friends, health, hobbies, and […]

The post Best Practices for Managing Work/Life Balance appeared first on StarFish Medical.

Hubble Protocol, A Solana-powered DeFi protocol, has successfully ended its Initial DEX Offering (IDO) with 10,000 whitelisted users participating in the IDO and contributed over $1.2 million. The token launch was hosted on three different platforms at the same time. Hubble Nails Its IDO To join the crowdfunding event, whitelisted participants would need to meet [...]

The post Hubble Completes Successful IDO With Over $1.2 Million Worth of Distributed HBB Tokens appeared first on Blockonomi.

PHOENIX – Feb. 28, 2022 – onsemi (Nasdaq: ON), a leader in intelligent power and sensing technologies, is executing on its fab-liter manufacturing strategy with the ultimate goal of sustainable financial performance through gross margins expansion.

Last week the company signed a definitive agreement to divest its South Portland, Maine fab. Earlier this month, onsemi closed on the sale of its wafer fabrication facility in Oudenaarde, Belgium. As onsemi transitions production to more efficient fabs within its network, it will improve its cost structure by eliminating fixed costs associated with the sold fabs and lowering its unit costs.

“The proposed divestitures show that we are well on our way to achieve an optimized manufacturing network while supporting our customers with long-term assurance of supply,” said Hassane El-Khoury, president and chief executive officer of onsemi. “The transactions provide employees at the affected fabs with continued employment and growth opportunities while allowing onsemi to transition production from these fabs to other manufacturing sites in an orderly manner.”

onsemi and Diodes Incorporated entered into a definitive agreement for the divestiture of onsemi’s wafer fabrication facility and operations in South Portland, Maine. Diodes plans to expand on its 200mm wafer fab capacity in support of its analog product growth. The transaction is expected to close in the second quarter of 2022.

On February 8, 2022, onsemi completed the sale of its manufacturing facility in Oudenaarde, Belgium to BelGaN Group BV, a consortium of investors and executives with extensive expertise in semiconductors, BelGaN plans to become a leading 6-inch and 8-inch gallium nitride (GaN) foundry in Belgium.

Technological advancements have seen the logistics industry flourish. Manual tasks can now be done either online or completely autonomously. These advancements have seen an increase in efficiency across the board which will only continue with ever-growing technological development. One such development that is already influencing the logistics industry is sustainable vehicles. Sustainable vehicles refer to vehicles like electric vehicles – EVs (that run on electric motors) and hybrid electric vehicles (internal combustion engine and electric propulsions). Some countries in Asia, America and Europe have begun to make the change to electric vehicles so that the transportation of goods is more […]

The post Super Charged: Electric Vehicles in the Modern Supply Chain appeared first on 20Cube Logistics.